CA2296373A1 - Composition and method for treating penile erectile dysfunction - Google Patents

Composition and method for treating penile erectile dysfunction Download PDF

Info

Publication number
CA2296373A1
CA2296373A1 CA002296373A CA2296373A CA2296373A1 CA 2296373 A1 CA2296373 A1 CA 2296373A1 CA 002296373 A CA002296373 A CA 002296373A CA 2296373 A CA2296373 A CA 2296373A CA 2296373 A1 CA2296373 A1 CA 2296373A1
Authority
CA
Canada
Prior art keywords
composition
prostaglandin
erectile dysfunction
penile erectile
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002296373A
Other languages
French (fr)
Other versions
CA2296373C (en
Inventor
Carlos M. Samour
Scott F. Krauser
Robert J. Gyurik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Macrochem Corp
Original Assignee
Macrochem Corporation
Carlos M. Samour
Scott F. Krauser
Robert J. Gyurik
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macrochem Corporation, Carlos M. Samour, Scott F. Krauser, Robert J. Gyurik filed Critical Macrochem Corporation
Publication of CA2296373A1 publication Critical patent/CA2296373A1/en
Application granted granted Critical
Publication of CA2296373C publication Critical patent/CA2296373C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Beans For Foods Or Fodder (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A composition for the topical transdermal administration to the penis is based on prostaglandin E1. The composition is non-irritating and effective for relieving erectile impotence or other penile erectile dysfunction. A penetration enhancing effective amount of a dioxolane, dioxane, or acetal skin penetration enhancing compound in a pharmaceutically acceptable aqueous alcoholic carrier is used to facilitate the penetration of the prostaglandin E1 active ingredient through the skin.
Phentolamine or prazosin may be used in combination with or in I
place of prostaglandin E1.
CA002296373A 1998-06-15 1998-06-15 Composition and method for treating penile erectile dysfunction Expired - Fee Related CA2296373C (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1998/012284 WO1999065303A1 (en) 1998-06-15 1998-06-15 Composition and method for treating penile erectile dysfunction

Publications (2)

Publication Number Publication Date
CA2296373A1 true CA2296373A1 (en) 1999-12-23
CA2296373C CA2296373C (en) 2003-08-12

Family

ID=22267309

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002296373A Expired - Fee Related CA2296373C (en) 1998-06-15 1998-06-15 Composition and method for treating penile erectile dysfunction

Country Status (18)

Country Link
US (1) US5942545A (en)
EP (1) EP1026947B1 (en)
JP (1) JP3513764B2 (en)
KR (1) KR20010022296A (en)
CN (1) CN1206998C (en)
AT (1) ATE209856T1 (en)
AU (1) AU764437B2 (en)
BR (1) BR9811797A (en)
CA (1) CA2296373C (en)
DE (1) DE69802838T2 (en)
DK (1) DK1026947T3 (en)
ES (1) ES2170503T3 (en)
HK (1) HK1030133A1 (en)
HU (1) HU224318B1 (en)
IL (1) IL134191A0 (en)
NO (1) NO20000157L (en)
PL (1) PL189436B1 (en)
WO (1) WO1999065303A1 (en)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251436B1 (en) 1995-09-29 2001-06-26 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
GR1002847B (en) 1997-05-06 1998-01-27 Use of micropostol and/or micropostol acid for the preparation of a medicine for the therapeutic treatiment of problems related to the erection
US6414028B1 (en) * 1997-11-05 2002-07-02 Nexmed Holdings, Inc. Topical compositions containing prostaglandin E1
WO2002069966A1 (en) * 2001-03-05 2002-09-12 Usa Doctors Products, Inc. Injectable pharmaceutical composition for treatment and reversal of erectile dysfunction
GR1003199B (en) 1998-08-14 1999-09-01 Use of micropostol and/or micropostol acid for the preparation of a medicine for the therapeutic threatment of problemes related to the female sexual malfunction
FR2789586A1 (en) * 1999-02-16 2000-08-18 Synthelabo Compositions containing alfuzosin for treatment of erectile dysfunction, applied by balanic transmucosal administration
WO2000051978A1 (en) 1999-03-01 2000-09-08 Nitromed, Inc. Nitrosated and nitrosylated prostaglandins, compositions and metods of use
PL350917A1 (en) 1999-03-05 2003-02-10 Procter & Gamble C16 unsaturated fp-selective prostaglandins analogs
WO2001008659A1 (en) * 1999-07-30 2001-02-08 Lakefield Minerals Ltd. Pharmaceutical compositions for topical application to treat erectile dysfunction
US6730065B1 (en) * 2000-09-15 2004-05-04 Ocularis Pharma, Inc. Night vision composition
US6582683B2 (en) 2000-01-04 2003-06-24 Skinvisible Pharmaceuticals, Inc. Dermal barrier composition
US6693135B2 (en) 2000-01-10 2004-02-17 Nexmed (Holdings) Incorporated Prostaglandin compositions and methods of treatment for male erectile dysfunction
US6323241B1 (en) * 2000-01-10 2001-11-27 Nexmed (Holdings) Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
US7105571B2 (en) * 2000-01-10 2006-09-12 Nexmed Holdings, Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
US20020013294A1 (en) 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
KR100402334B1 (en) * 2000-06-23 2003-10-22 환인제약 주식회사 Alprostadil-containing composition for external application
WO2002007757A2 (en) * 2000-07-21 2002-01-31 Lue Tom F Prevention and treatment of sexual arousal disorders
US7223406B2 (en) * 2000-07-21 2007-05-29 The Regents Of The University Of California Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder
CA2416709A1 (en) * 2000-07-31 2003-01-17 Ono Pharmaceutical Co., Ltd. Therapeutic agent for erectile dysfunction containing as the active ingredient prostaglandin derivatives
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
KR100649860B1 (en) * 2000-09-01 2006-11-24 주식회사종근당 Transmucosal and transdermal delivery preparation of alprostadil
KR20020020536A (en) * 2000-09-09 2002-03-15 장우영 Injection for impotency
KR100373540B1 (en) * 2000-09-20 2003-02-25 최한곤 Composite of transurethral suppository containing prostaglandin E1
US20060211753A1 (en) * 2000-11-03 2006-09-21 Ocularis Pharma, Inc. Method and composition which reduces stimulation of muscles which dilate the eye
AU2002242875C1 (en) * 2001-03-30 2006-08-10 Futura Medical Developments Limited Condom with an erectogenic composition
US20030138494A1 (en) * 2001-05-15 2003-07-24 L.A.M. Pharmaceutical Corporation Drug preparations for treating sexual dysfunction
US7244703B2 (en) * 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
US6756059B2 (en) * 2001-08-20 2004-06-29 Skinvisible Pharmaceuticals, Inc. Topical composition, topical composition precursor, and methods for manufacturing and using
WO2003022239A2 (en) * 2001-09-07 2003-03-20 Western Holdings Llc Stable water in oil aminophylline emulsions
KR100446960B1 (en) * 2001-12-04 2004-09-01 김종국 Composition of thermosensitive emulsion for external use of prostaglandin E1
KR100810404B1 (en) * 2001-12-18 2008-03-04 환인제약 주식회사 Alprostadil alkyl ester-containing composition for external application
US6673841B2 (en) 2001-12-20 2004-01-06 Whan In Pharm. Co., Ltd. Alprostadil alkyl ester-containing composition for external application
CN1610559A (en) * 2002-02-15 2005-04-27 奈克斯麦德控股有限公司 Prostaglandin composition for the treatment of erectile dysfunction
US6919348B2 (en) * 2002-05-02 2005-07-19 Edward T. Wei Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith
US20030219696A1 (en) * 2002-05-23 2003-11-27 Moreland Gerald W. Method and apparatus for preventing backflow in dental saliva evacuators
GB0222522D0 (en) 2002-09-27 2002-11-06 Controlled Therapeutics Sct Water-swellable polymers
US20040126339A1 (en) * 2002-12-31 2004-07-01 Roszell James A. Sunscreen composition and methods for manufacturing and using a sunscreen composition
US6841574B2 (en) * 2003-01-03 2005-01-11 Nexmed Holdings, Inc. Topical stabilized prostaglandin E compound dosage forms
US20050181030A1 (en) * 2003-01-03 2005-08-18 Mo Y. J. Topical stabilized prostaglandin E compound dosage forms
KR20050119136A (en) * 2003-03-21 2005-12-20 넥스메드 홀딩스 인코포레이티드 Angiogenesis promotion by prostaglandin compositions and methods
EP1605928A1 (en) 2003-03-21 2005-12-21 Nexmed Holdings, Inc. Compositions and methods for treatment of premature ejaculation
EP1608378A1 (en) * 2003-04-02 2005-12-28 Nexmed (Holdings), Inc. Prostaglandin compositions and their use for the treatment of vasospasm
US20050049311A1 (en) * 2003-09-03 2005-03-03 Pharmacia & Upjohn Company Medicinal products comprising prostaglandin compositions and methods of packaging such compositions
BRPI0418589A (en) * 2003-12-08 2008-01-29 Bentley Pharmaceuticals Inc pharmaceutical compositions and methods for insulin treatment
GB0417401D0 (en) 2004-08-05 2004-09-08 Controlled Therapeutics Sct Stabilised prostaglandin composition
US20060127483A1 (en) * 2004-12-10 2006-06-15 Alan Drizen Topical drug delivery system
TR201815853T4 (en) 2005-10-12 2018-11-21 Besins Healthcare Sarl Testosterone gel for use in the treatment of hypogonadism.
GB0613333D0 (en) 2006-07-05 2006-08-16 Controlled Therapeutics Sct Hydrophilic polyurethane compositions
GB0613638D0 (en) 2006-07-08 2006-08-16 Controlled Therapeutics Sct Polyurethane elastomers
US7560489B2 (en) * 2006-10-11 2009-07-14 Nexmed Holdings, Inc. Stabilized prostaglandin E composition
GB0620685D0 (en) 2006-10-18 2006-11-29 Controlled Therapeutics Sct Bioresorbable polymers
WO2008066618A2 (en) * 2006-10-20 2008-06-05 Skinvisible Pharmaceuticals, Inc. Antifungal composition and methods for using
US9005183B2 (en) * 2007-05-16 2015-04-14 Health Knight, Llc System and method for treating erectile dysfunction
US8128913B1 (en) 2007-12-06 2012-03-06 Skinvisible Pharmaceuticals, Inc. Sunscreen composition with enhanced UV-A absorber stability and methods
BRPI0800596A2 (en) 2008-01-31 2009-09-22 Univ Minas Gerais method for potentiation of erectile function through the use of pharmaceutical compositions of the toxin tx2-6 from the phoneutria nigriventer spider
US8299122B2 (en) * 2008-04-14 2012-10-30 Skinvisible Pharmaceuticals, Inc. Method for stabilizing retinoic acid, retinoic acid containing composition, and method of using a retinoic acid containing composition
US8940794B2 (en) 2011-04-07 2015-01-27 Nexmed Holdings, Inc. Methods and compositions for treating Raynaud's disease
US20230022570A1 (en) * 2019-12-09 2023-01-26 Futura Medical Developments Limited Topical composition
CA3074150A1 (en) 2020-02-18 2021-08-18 Ovation Science, Inc. Composition and method for transdermal delivery of cannabidiol (cbd) and delta9-tetrahydrocannabinol (thc)
WO2022087496A1 (en) * 2020-10-22 2022-04-28 Standard International Group Holdings, LP Transdermal treatment for erectile dysfunction

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4127118B1 (en) * 1977-03-16 1995-12-19 Alvaro Latorre Method of effecting and enhancing an erection
US4311707A (en) * 1979-02-12 1982-01-19 American Cyanamid Company Process for topically producing cutaneous vasodilation for the treatment of vasospastic or ischemic conditions
US4861764A (en) * 1986-11-17 1989-08-29 Macro Chem. Corp. Percutaneous absorption enhancers, compositions containing same and method of use
US5219885A (en) * 1987-02-16 1993-06-15 Froelich Juergen Prostaglandin E1 derivatives as pharmaceutically active agents, and pharmaceutical compositions containing these compounds, especially for transcutaneous administration
US4801587A (en) * 1987-03-02 1989-01-31 Gene Voss Impotence ointment
US5256652A (en) * 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
SE463851B (en) * 1988-09-02 1991-02-04 Amsu Ltd COMPOSITION FOR TREATMENT OF ERECT DYSFUNCTION THROUGH URETRA
AU616571B2 (en) * 1988-10-28 1991-10-31 Shiseido Company Ltd. Cosmetic composition containing inclusion product with hydroxyalkylated cyclodextrin
US5059603A (en) * 1989-06-12 1991-10-22 Centuries Laboratories, Inc. Method and composition for treating impotence
FR2649613B1 (en) * 1989-07-11 1991-09-27 Virag Ronald VASO-ACTIVE MEDICINE
US5236904A (en) * 1989-09-18 1993-08-17 Senetek, Plc Erection-inducing methods and compositions
IT1252603B (en) * 1990-04-19 1995-06-19 Giorgio Cavallini 2,4-DIAMINO-6 PIPERIDINO PIRIMIDINA-3 TOPICAL OXIDE ON THE GLAND IN THE TREATMENT OF ERECTILE IMPOTENCES
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
IT1247678B (en) * 1990-05-31 1994-12-28 Alberto Reale METHOD FOR THE TREATMENT OF MALE ERECTIVE IMPOTENCE
US5270323A (en) * 1990-05-31 1993-12-14 Pfizer Inc. Method of treating impotence
US5399581A (en) * 1990-12-26 1995-03-21 Laragh; John H. Method and compositions for treatment of sexual impotence
DE4117249C2 (en) * 1991-05-27 1998-05-14 Christian Dr Stief Linsidomine used to treat erectile dysfunction
EP0618798B1 (en) * 1991-12-23 1997-03-12 PHARMACIA & UPJOHN COMPANY Pyridylguanidine compounds for treatment of erectile dysfunction
ATE169826T1 (en) * 1992-01-21 1998-09-15 Macrochem Corp IONTOPHORETIC IMPROVED DRUG DELIVERY
US5400094A (en) * 1993-03-31 1995-03-21 Minnesota Mining And Manufacturing Company Condensers for overhead projectors
US5439938A (en) * 1993-04-07 1995-08-08 The Johns Hopkins University Treatments for male sexual dysfunction
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
US5587167A (en) * 1993-09-14 1996-12-24 Choi; Hyung K. Pharmaceutical composition for prophylaxis and treatment of premature ejaculation
US5380760A (en) * 1993-11-19 1995-01-10 Minnesota Mining And Manufacturing Company Transdermal prostaglandin composition
US5482039A (en) * 1994-03-25 1996-01-09 Vivus, Inc. Process for diagnosing erectile dysfunction, and related methods of treatment
US5451609A (en) * 1994-07-27 1995-09-19 Institut De Recherches Chimiques Et Al Treatment of impotence
US5594032A (en) * 1994-11-10 1997-01-14 Gonzalez-Cadavid; Nestor F. Amelioration of human erectile dysfunction by treatment with iNOS, inducers of iNOS or iNOS cDNA
US5620980A (en) * 1995-02-22 1997-04-15 Macrochem Corporation Method for treating hair loss
US5583144A (en) * 1995-02-24 1996-12-10 Kral; John G. Methods for treating erectile impotence
US5968919A (en) * 1997-10-16 1999-10-19 Macrochem Corporation Hormone replacement therapy drug formulations for topical application to the skin

Also Published As

Publication number Publication date
ES2170503T3 (en) 2002-08-01
WO1999065303A1 (en) 1999-12-23
HK1030133A1 (en) 2001-04-27
EP1026947A1 (en) 2000-08-16
HUP0103346A2 (en) 2002-01-28
CA2296373C (en) 2003-08-12
NO20000157L (en) 2000-02-09
ATE209856T1 (en) 2001-12-15
AU7838798A (en) 2000-01-05
PL189436B1 (en) 2005-08-31
EP1026947A4 (en) 2000-10-25
CN1206998C (en) 2005-06-22
AU764437B2 (en) 2003-08-21
HUP0103346A3 (en) 2004-06-28
DE69802838D1 (en) 2002-01-17
PL338787A1 (en) 2000-11-20
JP2000511944A (en) 2000-09-12
HU224318B1 (en) 2005-07-28
BR9811797A (en) 2000-09-26
CN1267191A (en) 2000-09-20
DK1026947T3 (en) 2002-04-02
KR20010022296A (en) 2001-03-15
NO20000157D0 (en) 2000-01-12
JP3513764B2 (en) 2004-03-31
IL134191A0 (en) 2001-04-30
DE69802838T2 (en) 2002-06-27
EP1026947B1 (en) 2001-12-05
US5942545A (en) 1999-08-24

Similar Documents

Publication Publication Date Title
CA2296373A1 (en) Composition and method for treating penile erectile dysfunction
CA1146070A (en) Topical triethylenetetramine-containing pharmaceutical compositions and methods of use
AU620282B2 (en) Method of treating impotence
CA2420895A1 (en) Method for treating erectile dysfunction and increasing libido in men
EP1007013A4 (en) Parenteral pimaricin as treatment of systemic infections
CA2352552A1 (en) Treatment of erectile dysfunction
NZ520015A (en) Hydroxide-releasing agents as skin permeation enhancers
CA2033122A1 (en) Anti-inflammatory analgesic patch
EP0857488A1 (en) Methods and compositions for enhancing skin permeation of drugs using permeation enhancers
GR3032251T3 (en) Compositions containing prostaglandin e1 and/or troxerutine complexed with phosphatidylcholine for topical treatment of erectile impotence
DE69933128D1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF EFFECTIVE DYSFUNCTION
EP0489108A4 (en) Method and composition for the treatment of cutaneous, ocular, and mucosal hypersensitivity, inflammation, and hyperproliferative conditions using topical preparations of serotonin antagonists
WO2002019999A3 (en) Compositions for treating sexual dysfunction, containing an no-donor and an antioxidant
ATE303804T1 (en) TREATMENT OF SEXUAL DYSFUNCTION WITH BOMBESIN RECEPTOR ANTAGONISTS
CA2377373A1 (en) Nitric oxide donors for inducing neurogenesis
CA2284774A1 (en) Theobromine antitussive compositions
AU6848098A (en) Use of misoprostol or/and misoprostol acid for preparing drug in order to cu re erectile dysfunction
WO1999030718A3 (en) PROSTAGLANDIN E2/F2α COMBINATION FOR TREATING IMPOTENCE AND ENHANCING SEXUAL AROUSAL
WO1999065475A3 (en) Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
RU2000101317A (en) COMPOSITION AND METHOD OF TREATMENT OF DISORDERS OF PERFORMANCE OF THE PURPOSE

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed